hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06264024, orgStudyIdInfo id: 519516, briefTitle: Simultaneous pHototherapeutic Keratectomy and corneAl Collagen cRosslinking in Eyes With Keratoconus: a Randomized Trial (SHARK), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-12, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2034-02-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Oslo University Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare CXL with combined treatment with CXL and t-PTK.The main questions it aims to answer are whether combined treatment can give better visual acuity and if the treatments are equally safe., conditionsModule conditions: Keratoconus, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 81, type: ESTIMATED, armsInterventionsModule interventions name: Corneal collagen cross linking (CXL), interventions name: Transepithelial phototherapeutic keratectomy (t-PTK), outcomesModule primaryOutcomes measure: Visual acuity, primaryOutcomes measure: Risk of progression, secondaryOutcomes measure: Visual acuity, secondaryOutcomes measure: Visual acuity, secondaryOutcomes measure: Visual acuity, secondaryOutcomes measure: Visual acuity, secondaryOutcomes measure: Visual acuity, secondaryOutcomes measure: Risk of progression, secondaryOutcomes measure: Risk of progression, secondaryOutcomes measure: Risk of progression, secondaryOutcomes measure: Risk of progression, secondaryOutcomes measure: Risk of progression, secondaryOutcomes measure: Depth of demarcation line (OCT), secondaryOutcomes measure: Depth of demarcation line (confocal microscopy), secondaryOutcomes measure: Patient reported outcome measure (PROMs), secondaryOutcomes measure: Patient reported outcome measure (PROMs), secondaryOutcomes measure: Patient reported outcome measure (PROMs), secondaryOutcomes measure: Patient reported pain after surgery, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Ophhtalmology, University of Oslo, status: RECRUITING, city: Oslo, country: Norway, contacts name: Olav Kristianslund, MD, PhD, role: CONTACT, email: olakri@ous-hf.no, contacts name: Bjarne L Thorbjørnsen, MD, role: CONTACT, email: uxtbja@ous-hf.no, geoPoint lat: 59.91273, lon: 10.74609, hasResults: False
protocolSection identificationModule nctId: NCT06263998, orgStudyIdInfo id: HUC1-394, briefTitle: Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-03, primaryCompletionDateStruct date: 2025-11-28, completionDateStruct date: 2026-01-30, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Huons Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The objective is to evaluate the safety, local tolerability, and pharmacokinetics of NCP112 eye drops through single and multiple dose-escalation ocular administrations in healthy adults., conditionsModule conditions: Xerophthalmia, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: NCP112, interventions name: NCP112 Placebo, outcomesModule primaryOutcomes measure: Treatment-Emergent Adverse Events, secondaryOutcomes measure: Evaluation of pharmacokinetic profile, secondaryOutcomes measure: Evaluation of pharmacokinetic profile, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06263985, orgStudyIdInfo id: 20214133, briefTitle: Axis(TM) Solvent-dehydrate Dermal Allograft in the Treatment of Pelvic Organ Prolapse., statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2021-11-02, primaryCompletionDateStruct date: 2025-05-30, completionDateStruct date: 2025-05-30, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Michigan Institution of Women's Health PC, class: OTHER, collaborators name: Coloplast A/S, descriptionModule briefSummary: The goal of this study is to assess improvement in subjects who have undergone Axis Dermis, biologic mesh for pelvic organ prolapse repair. \[describe participant population/health conditions\]. The main question\[s\] it aims to answer are:* Is the leading edge of the prolapse above the hymen* Does subject notice a bulge Participants will undergo Axis Dermis pelvic organ prolapse repair procedure., conditionsModule conditions: Pelvic Organ Prolapse, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Subjects undergoing the treatment for pelvic organ prolapse with Axis Dermis biologic mesh., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ACTUAL, armsInterventionsModule interventions name: Axis Dermis biologic mesh repair for pelvic organ prolapse, outcomesModule primaryOutcomes measure: Improvement in function, primaryOutcomes measure: Improvement in Anatomy, secondaryOutcomes measure: Assess complications or untoward side effects., eligibilityModule sex: FEMALE, minimumAge: 21 Years, maximumAge: 89 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Advanced Urogynecology of Michigan, city: Dearborn, state: Michigan, zip: 48124, country: United States, geoPoint lat: 42.32226, lon: -83.17631, hasResults: False
protocolSection identificationModule nctId: NCT06263972, orgStudyIdInfo id: 0168-21EMC, briefTitle: Comparison of the Efficacy of Transcranial Direct Current Stimulation (tDCS) of the Primary Motor Cortex (M1) or the Prefrontal Cortex Combined With Aerobic Activity for Alleviation of Fibromyalgia Symptoms., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-07, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: HaEmek Medical Center, Israel, class: OTHER, collaborators name: Technion, Israel Institute of Technology, collaborators name: Rambam Health Care Campus, descriptionModule briefSummary: The goal of this study is to demonstrate the effectiveness of treating fibromyalgia using combination of electrical stimulation with aerobic activity.Participants will be randomly assigned to stimulation in a ratio of 1:1:1. 120 participants (40 in each group). The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation for 3 weeks., conditionsModule conditions: Fibromyalgia, conditions: Electric Shock, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Direct Stimulation Prefrontal Cortex, interventions name: Shame cortex stimulation, interventions name: Direct Stimulation to Motor Cortex, interventions name: erobic physical activity, outcomesModule primaryOutcomes measure: Study objectives: • Comparing the effectiveness of direct electric current stimulation between the two stimulus areas Numeric pain rating scale., primaryOutcomes measure: Study objectives: • Comparing the effectiveness of direct electric current stimulation (tDCS) between the two stimulus areas and in relation Adult sensory profile test Raw score., primaryOutcomes measure: Study objectives: • Comparing the effectiveness of direct electric current stimulation between the two stimulus areas and in relation to The Montreal Cognitive Assessment (MoCA) score., primaryOutcomes measure: Study objectives: • Comparing the effectiveness of direct electric current stimulation between the two stimulus areas and in relation to Generalized Anxiety Disorder 7-Item Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06263959, orgStudyIdInfo id: GST-HG131-II-01, briefTitle: A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-29, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2024-11-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Fujian Akeylink Biotechnology Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131 tablets in patients with chronic hepatitis B, conditionsModule conditions: Chronic Hepatitis B, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: GST-HG131, interventions name: Placebo to match GST-HG131, outcomesModule primaryOutcomes measure: Change from Baseline in HBsAg levels, secondaryOutcomes measure: Number of participants with adverse events (AEs), serious adverse events (SAEs), and withdrawals due to AEs, eligibilityModule sex: ALL, minimumAge: 35 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Fifth Medical Center of Chinese PLA General Hospital, status: RECRUITING, city: Beijing, country: China, contacts name: Tang Yanan, role: CONTACT, phone: +8613585734994, email: annie_tyn@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06263933, orgStudyIdInfo id: 2023-A01804-41, briefTitle: Effect of Experience Sharing and Mutual Assistance on Insight and Recovery During the First Psychotic Episode, acronym: DIPEM, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-13, primaryCompletionDateStruct date: 2024-11-13, completionDateStruct date: 2025-11-13, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Centre hospitalier de Ville-Evrard, France, class: OTHER, descriptionModule briefSummary: Controlled, prospective, qualitative and quantitative trial. The goal of this trial is to evaluate the mutual assistance early intervention device efficacy and its impact on insight and personal recovery of participants living with a first psychotic episode. This intervention lasts 5 days with 1 session per day of 1 hour 30 minutes. Three evaluations, before the intervention, after intervention and 1 month after the hospitalization's end., conditionsModule conditions: Psychotic Episode, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A control group and a intervention group, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Insight Scale, interventions name: Semi-directional interviews, interventions name: routine care, interventions name: session of mutual assistance with a mediator psychologist, outcomesModule primaryOutcomes measure: The level of the increasing of The INSIGHT scale, secondaryOutcomes measure: The increase of Recovery Scale, secondaryOutcomes measure: The semi-structured interview, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Etablissement Public de Santé de Ville-Evrard, status: RECRUITING, city: Neuilly-sur-Marne, zip: 93330, country: France, contacts name: Rusheenthira Thavaseelan, role: CONTACT, phone: 0143093232, phoneExt: 033, email: r.thavaseelan@epsve.fr, contacts name: Dominique Januel, role: CONTACT, phone: 0143093232, phoneExt: 033, email: d.januel@epsve.fr, contacts name: Dominique Januel, Pr, role: PRINCIPAL_INVESTIGATOR, contacts name: Ilona Arcomano, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 48.85373, lon: 2.54903, hasResults: False
protocolSection identificationModule nctId: NCT06263907, orgStudyIdInfo id: stellate ganglion block, briefTitle: Stellate Ganglion Block for Prevention of Post Mastectomy Depression, acronym: SGB, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Mansoura University, class: OTHER, descriptionModule briefSummary: Complications after mastectomy include chronic pain and depression., conditionsModule conditions: Mastectomy, conditions: Pain, Acute, conditions: Pain, Chronic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Patients will be randomization into two equal groups using computer-generated random numbers prior to surgery of 70 each; Group S: will receive ipsilateral stellate gangalion block and Group C: will receive no block., primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, maskingDescription: The anesthesiologist, who will be responsible for opening the envelope and do the block or not according to the group besides, evaluation of its success and covering the skin over the site of ipsilateral stellate gangalion with sterile dressing in both groups, will not be involved in data collection., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: Stellate gangalion block, outcomesModule primaryOutcomes measure: incidence of postmastectomy depression, secondaryOutcomes measure: incidence of postmastectomy depression, secondaryOutcomes measure: the need for postoperative antidepressant, secondaryOutcomes measure: acute postoperative pain at the incision site (breast and the axilla), secondaryOutcomes measure: chronic postmastectomy pain at the incision site, secondaryOutcomes measure: incidence of nausea and vomiting, secondaryOutcomes measure: Functional pain in the ipsilateral shoulder, secondaryOutcomes measure: Any complications related to stellate ganglion injection, eligibilityModule sex: FEMALE, minimumAge: 21 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06263894, orgStudyIdInfo id: MarmaraU-Ebe-ZDY-01, briefTitle: Alexander Technique on Labor Pain and Anxiety, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-05, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-07-02, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Marmara University, class: OTHER, collaborators name: The Scientific and Technological Research Council of Turkey, descriptionModule briefSummary: This study will examine the effect of the Alexander Technique on labor pain and anxiety during labor. This study is designed as a randomized controlled experimental study. The population of the study consists of primiparous pregnant women who applied to Istanbul Provincial Health Directorate Başakşehir Çam and Sakura City Hospital, D-Block Maternity Hospital between November 2023 and May 2024. In calculating the sample size, G\*Power (3.1.9.6) program was used to calculate the sample size with an error of 0.05, effect level of 0.5, power of 95%, and the required sample size for 2 groups was calculated as 34 people for each group with a total of 68 people., conditionsModule conditions: Labor Pain, conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: One experimental group and one conventional (control) group, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, maskingDescription: In order to reduce selection bias in determining the experimental and control groups, a computer-assisted randomization program (https://www.randomizer.org) will be used for pregnant women who meet the inclusion criteria., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 68, type: ESTIMATED, armsInterventionsModule interventions name: Experimental group, outcomesModule primaryOutcomes measure: Decreasing labor pain, primaryOutcomes measure: Decreasing anxiety, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Başakşehir Çam and Sakura City Hospital, status: RECRUITING, city: Istanbul, country: Turkey, contacts name: Ayşen Özgür, role: CONTACT, phone: +905393806296, email: aysenozgurr@gmail.com, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06263855, orgStudyIdInfo id: 24-000352, briefTitle: Effect of Large Language Model in Assisting Discharge Summary Notes Writing for Hospitalized Patients, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This pilot study aims to assess the feasibility of carrying out a full-scale pragmatic, cluster-randomized controlled trial which will investigate whether discharge summary writing assisted by a large language model (LLM), called CURE (Checker for Unvalidated Response Errors), improves care delivery without adversely impacting patient outcomes., conditionsModule conditions: Large Language Model, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 1015, type: ESTIMATED, armsInterventionsModule interventions name: CURE, outcomesModule primaryOutcomes measure: Rate of patient accrual, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic, city: Rochester, state: Minnesota, zip: 55905, country: United States, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06263829, orgStudyIdInfo id: 2023-1580, briefTitle: HCV Tappt Adherence Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-07-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: University of Illinois at Chicago, class: OTHER, collaborators name: Synchronyx, collaborators name: American Society of Health-System Pharmacists, descriptionModule briefSummary: The goal of this non-inferiority clinical trial is to evaluate the efficacy of Tappt, a novel digital medication companion solution, among individuals with hepatitis C virus (HCV) who are starting a daily oral medication regimen following standard of care in a clinical pharmacy setting.* The primary aim is to assess the non-inferiority of Tappt with medication adherence, treatment completion, sustained virologic response (SVR) assessment, and SVR achievement rates.* The secondary aim is to assess the efficacy of Tappt at enabling pharmacists to personalize treatment and management decision based on participants' reported barriers to adherence, care, and SVR achievement.Participants will download and utilize the Tappt app to record adherence to oral medication. For the purposes of this study, adherence for participants in the intervention arm will be measured using a modified medication possession ratio (MPR) measure called medication tag scan ratio (MTSR). MTSR is defined as a percentage of the number of times participants scanned their passive tags versus the total of expected tag scans based on that participant's medication regimen and treatment period.Upon study completion, a retrospective matched control will be established for the intervention group. Historic data for the matched control's adherence, treatment completion, SVR assessment, and SVR rates will be compared to the intervention arm., conditionsModule conditions: Hepatitis C, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Use of Tappt App, outcomesModule primaryOutcomes measure: Medication adherence, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06263803, orgStudyIdInfo id: Karataymusic, briefTitle: The Effect of Listening to Music on Chronic Low Back Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-04-15, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: KTO Karatay University, class: OTHER, descriptionModule briefSummary: The effects of passive music listening on pain, anxiety and quality of life in patients with chronic low back pain in addition to physical therapy will be examined., conditionsModule conditions: Pain, Chronic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: single, whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Music listening, classic physical therapy, outcomesModule primaryOutcomes measure: Beck anxiety inventory, primaryOutcomes measure: Visual Analogue Scale, primaryOutcomes measure: Short From-36, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Mustafa Savaş Torlak, status: RECRUITING, city: Karatay, state: Eyalet/Yerleşke, zip: 42000, country: Turkey, contacts name: Mustafa S Torlak, role: CONTACT, phone: +905373660138, email: mustafa.savas.torlak@karatay.edu.tr, geoPoint lat: 37.86726, lon: 32.52863, hasResults: False